CTS-Clinical and Translational Science

Article	Citations
Issue Information	300
Gene polymorphism and prediction of toxicity to platinum‐based chemotherapy in patients with gynecologic cancer	135
Mitigating ipatasertib‐induced glucose increase through dose and meal timing modifications	100
Expression of Concern:Zhou, Y., & Zhou, J.Tranilast Treatment Attenuates Cerebral Ischemia‐Reperfusion Injury in Rats Through the Inhibition of Inflammatory Responses Mediated by NF‐κB and	66
Issue Information	62
First, Do No Harm: Addressing AI's Challenges With Out‐of‐Distribution Data in Medicine	62
From Lab to Clinic: Effect of Academia–Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry	55
ST2 and CSF‐1 as potential druggable targets of inflammatory bowel diseases: Results from two‐sample Mendelian randomization study	53
Perspectives on Using Pharmacogenomics to Guide Tobacco Cessation: Survey Results From an American Indian Community	47
Japanese Phase 1 Study for Global Development of Anti‐TL1A Antibody PF‐06480605: A Randomized, Placebo‐Controlled, Single‐Ascending Dose Study	46
Nontraditional Factors Influencing Cardiovascular Disease Risk: Correlation Among Framingham Risk Score, Body Composition Index, and Sleep‐Breathing Monitoring Index	45
Model‐informed assessment of ethnic sensitivity and dosage justification for Asian populations in the global clinical development and use of cladribine tablets	44
Pharmacogenomic polygenic risk score for clopidogrel responsiveness among Caribbean Hispanics: A candidate gene approach	42
Evidence of depot‐specific regulation of all‐trans‐retinoic acid biosynthesis in human adipose tissue	41
Patient, industry, and regulatory perspective on antibody‐drug conjugates dose optimization	37
Pharmacogenomic landscape of Indian population using whole genomes	37
CYP3A Genotype Is Associated With Variability in the Exposure and Clearance of the Novel Oncogenic Transcription Inhibitor Lurbinectedin	36
Expanding regulatory science: Regulatory complementarity and reliance	35
A Patient Centric Model for Vaso‐Occlusive Crises in Sickle Cell Disease—Outcomes of a Consensus Exercise Conducted Across Patients and Experts	35
The impact of skin color and tone on histamine iontophoresis and Doppler flowmetry measurements as a pharmacodynamic biomarker	34
Developing a clinical research infrastructure embedded in an academic medicine center that equitably supports future clinician scientists	29
Intradermal substance P as a challenge agent in healthy individuals	29
Using partition analysis as a facile method to derive net clearances	29
Pharmacokinetics of Sofosbuvir/Velpatasvir and efficacy of an alternate‐day treatment in hemodialysis patients with chronic hepatitis C infection	28
A comprehensive Thai pharmacogenomics database (TPGxD‐1): Phenotype prediction and variants identification in 942 whole‐genome sequencing data	28

First‐in‐human study of JNJ‐67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndrome	26
Generalizability in real‐world trials	26
Emapalumab in Patients With Macrophage Activation Syndrome Associated With Still's Disease: A Population Pharmacokinetic/Pharmacodynamic Analysis	26
Evidence–time dilemma in a pandemic with high mortality: Can outcome‐driven decision making on vaccines prevent deaths?	26
Risk factors for the development of sepsis in patients with cirrhosis in intensive care units	26
Lexicon for blood‐based early detection and screening: BLOODPAC consensus document	26
Gossypol improves myocardial dysfunction caused by sepsis by regulating histone acetylation	25
Population pharmacokinetic analysis of quizartinib in patients with newly diagnosed FLT3‐internal‐tandem‐duplication‐positive acute myeloid leukemia	25
Population‐based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma	24
Risk Factors Analysis of Cutaneous Adverse Drug Reactions Caused by Targeted Therapy and Immunotherapy Drugs for Oncology and Establishment of a Prediction Model	24
Feasibility study for a fully decentralized clinical trial in participants with functional constipation symptoms	23
Recommended Clinical Context and Patient Context Data Elements for Liquid Biopsy Data Submitted to Data Repositories and Data Commons	23
Comprehensive analysis of clinical and biological features in Parkinson's disease associated with the LRRK2 G2019S mutation: Data from the PPMI study	23
Precision Antiplatelet Therapy after Percutaneous Coronary Intervention (Precision PCI) Registry – Informing optimal antiplatelet strategies	22
Investigation of pharmacokinetic drug interaction between clesacostat and DGAT2 inhibitor ervogastat in healthy adult participants	22
Exploring the discrepancies between clinical trials and real‐world data: A small‐cell lung cancer study	22
Prevalence of actionable pharmacogenetic variants and high‐risk drug prescriptions: A Swiss hospital‐based cohort study	21
Phase 1 Study Evaluating the Pharmacokinetics, Dose Proportionality, Bioavailability, and Tolerability of Subcutaneous Levothyroxine Sodium (XP‐8121)	21
First‐in‐human study evaluating safety, pharmacokinetics, and pharmacodynamics of lorundrostat, a novel and highly selective aldosterone synthase inhibitor	21
Real‐world evidence to support regulatory submissions: A landscape review and assessment of use cases	21
Safety, pharmacokinetics, and target engagement of a brain penetrant RIPK1 inhibitor, SAR443820 (DNL788), in healthy adult participants	20
Pharmacokinetics and safety of cenobamate, a novel antiseizure medication, in healthy Japanese, and an ethnic comparison with healthy non‐Japanese	20
Human radiolabeled mass balance studies supporting the FDA approval of new drugs	20
Efficacy and safety of tofacitinib in rheumatoid arthritis: Nine years of real‐world data	20
Parkinson's disease: Still waiting for a cure	20
Cardiovascular risk of urate‐lowering drugs: A study using the National Database of Health Insurance Claims and Specific Health Checkups of Japan	19
Hesitant adopters: An examination of hesitancy among adults in Arkansas who have taken the COVID‐19 vaccine	19
Use cases of registry‐based randomized controlled trials—A review of the registries' contributions and constraints	19
Pediatric CYP2D6 metabolizer status and post‐tonsillectomy nausea and vomiting after ondansetron	19
Posaconazole and midostaurin in patients with FLT3‐mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study	19
Comparing machine learning and deep learning models to predict cognition progression in Parkinson's disease	19
Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine‐kinase inhibitors	19
Vericiguat, a novel sGC stimulator: Mechanism of action, clinical, and translational science	19
Toward pharmacogenetic SLCO1B1‐guided dosing of methotrexate in arthritis using a murine Slco1b2 knockout model	18
Evaluation of the potential drug interactions mediated through P‐gp, OCT2, and MATE1/2K with filgotinib in healthy subjects	18
No implication of HIV coinfection on the plasma exposure to rifampicin, pyrazinamide, and ethambutol in tuberculosis patients	18
Transarterial Chemoembolization for Patients With Hepatocellular Carcinoma Using Miriplatin Without the Need for Hydration	17
Clinical Pharmacology Overview of Tislelizumab in Patients With Advanced Tumors With a Focus on Racial Impact	17
Effect of Selective Serotonin Reuptake Inhibitors on Coagulation: Fact or Fiction?	17
Real‐world evidence in the cloud: Tutorial on developing an end‐to‐end data and analytics pipeline using Amazon Web Services resources	17
Issue Information	17
The Role of Candidate Polymorphisms in Drug Transporter Genes on High‐Dose Methotrexate in the Consolidation Phase of the AIEOP‐BFM ALL 2009 Protocol	17
A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID‐19	17
Associations of HLA genetic variants with carbamazepine‐induced cutaneous adverse drug reactions: An updated meta‐analysis	17
Phase I and scintigraphy studies to evaluate safety, tolerability, pharmacokinetics, and lung deposition of inhaled GDC‐0214 in healthy volunteers	17
Issue Information	16
Lidocaine as an anti‐arrhythmic drug: Are there any indications left?	16
Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment	16
Issue Information	16
A Tutorial and Use Case Example of the eXtreme Gradient Boosting (XGBoost) Artificial Intelligence Algorithm for Drug Development Applications	16

Pharmacogenetic variants of infliximab response in young patients with inflammatory bowel disease	16
	16
Real‐world implementation of DPYD and UGT1A1 pharmacogenetic testing in a community‐based cancer center	16
Issue Information	15
Issue Information	15
Engaging student opinions on vaccine development innovation: Experiences from a “Shark Tank” project	15
Psoriasis Risk Is Lower in Type 2 Diabetes Patients Using Dipeptidyl Peptidase‐4 Inhibitors or Thiazolidinediones Compared to Sulfonylureas	15
Issue Information	15
Population pharmacokinetics and exposure‐response modeling analyses of guselkumab in patients with psoriatic arthritis	15
Penetration of linezolid and tedizolid in cerebrospinal fluid of mouse and impact of blood–brain barrier disruption	15
High intrapatient variability of tacrolimus exposure associated with poorer outcomes in liver transplantation	14
Free heme and hemopexin in acute kidney injury after cardiopulmonary bypass and transient renal ischemia	14
A First‐In‐Human Phase 1 Study to Evaluate the Safety and Tolerability of LEM‐S401, a Novel siRNA‐DegradaBALL Drug Targeting CTGF in Healthy Adul	14
Model‐informed precision dosing of teicoplanin for the rapid achievement of the target area under the concentration‐time curve: A simulation study	14
Prediction of molecular phenotypes for novel SCN1A variants from a Turkish genetic epilepsy syndromes cohort and report of two new patients with recessive Dravet syndrome	14
	14
The “One‐Step” approach for QT analysis increases the sensitivity of nonclinical QTc analysis	14
CYP2C8*3 and *4 define CYP2C8 phenotype: An approach with the substrate cinitapride	14
Issue Information	14
Pharmacokinetic evaluation of radiolabeled intraocular anti‐CLEC14a antibody in preclinical animal species and application in humans	14
Predicted expression of genes involved in the thiopurine metabolic pathway and azathioprine discontinuation due to myelotoxicity	13
PBPK‐led assessment of antimalarial drugs as candidates for Covid‐19: Simulating concentrations at the site of action to inform repurposing strategies	13
Safety and pharmacokinetics of docetaxel in combination with pegvorhyaluronidase alfa in patients with non‐small cell lung cancer	13
Artificial intelligence in rare disease diagnosis and treatment	13
Metabolomic signatures of carfilzomib‐related cardiotoxicity in patients with multiple myeloma	13
Academia and industry agreement on a feasibility tool for first‐time‐in‐human clinical trial units	13
Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach	13
Machine learning framework to predict pharmacokinetic profile of small molecule drugs based on chemical structure	13
What motivates people with type 2 diabetes mellitus to participate in clinical trials from home?	13
Association between statin use and dry eye disease in patients with hyperlipidemia: A population‐based retrospective cohort study	13
Integrating real‐world data and machine learning: A framework to assess covariate importance in real‐world use of alternative intravenous dosing regimens for atezolizumab	13
Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta‐analysis	13
Dupilumab: Mechanism of action, clinical, and translational science	13
	12
An overview of drug‐induced sodium channel blockade and changes in cardiac conduction: Implications for drug safety	12
Population pharmacokinetic and pharmacodynamic modeling of evobrutinib in healthy adult participants	12
MicroRNA sequencing in patients with coronary artery disease – considerations for use as biomarker for thrombotic risk	12
The effect of age on blood pressure response by 4‐week treatment perindopril: A pooled sex‐specific analysis of the EUROPA, PROGRESS, and ADVANCE trials	12
Clinical pharmacokinetics and pharmacodynamics of ongericimab: A potential long‐acting PCSK9 monoclonal antibody in healthy subjects and patients with hypercholesterolemia: Randomized, double‐blind, p	12
A Patient‐Derived 3D Cyst Model of Polycystic Kidney Disease That Mimics Disease Development and Responds to Repurposing Candidates	12
Application of a patient‐centered reverse translational systems‐based approach to understand mechanisms of an adverse drug reaction of immune checkpoint inhibitors	12
Evaluation of drug‐drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically‐based pharmacokinetic	12
Effect of carrot intake on glucose tolerance, microbiota, and gene expression in a type 2 diabetes mouse model	12
Oral and intravenous pharmacokinetics of metformin with and without oral codeine intake in healthy subjects: A cross‐over study	12
Prediction of Cisplatin‐Induced Acute Kidney Injury Using an Interpretable Machine Learning Model and Electronic Medical Record Information	12
Anticoagulant therapy in COVID‐19: A narrative review	12
Lay understandings of drug‐gene interactions: The right medication, the right dose, at the right time, but what are the right words?	12
COVID‐19 vaccine hesitancy: Race/ethnicity, trust, and fear	12
Response to “DPYD genotyping panels: Impact of population diversity”	11
Physiologically based absorption modeling to predict the bioequivalence of two apixaban formulations	11
Preclinical assessment of drug–drug interaction of fb‐PMT, a novel anti‐cancer thyrointegrin αvβ3 antagonist	11
Association between aortic calcification and cytokine levels in patients with peripheral artery disease	11
Optimizing expert and patient input in pediatric trial design: Lessons learned and recommendations from a collaboration between conect4children and European Patient‐CEntric ClinicAl TRial PLatforms	11
Leveraging patient‐centric sampling for clinical drug development and decentralized clinical trials: Promise to reality	11
A phase I randomized, double‐blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects	11
Endogenous metabolic markers for predicting the activity of dihydropyrimidine dehydrogenase	11
Inhibition of Tacrolimus Metabolism by Cannabidiol and Its Metabolites In Vitro	11
A drug‐disease model for predicting survival in an Ebola outbreak	11
Proposing a framework to quantify the potential impact of pharmacokinetic drug–drug interactions caused by a new drug candidate by using real world data about the target patient population	11
Safety, pharmacokinetics, and pharmacodynamics of ART‐648, a PDE4 inhibitor in healthy subjects: A randomized, placebo‐controlled phase I study	11
Comparison of glutaminase and cancer antigen 125 for distinguishing benign and malignant ovarian tumors	11
Feasibility of preemptive pharmacogenetic testing and improvement of medication treatment satisfaction among medically underserved patients	11
	11
Issue Information	11
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INT‐787, a Novel Farnesoid X Receptor Agonist, in Healthy Volunteers: A Phase 1 Trial	11
Evaluation of potential drug–drug interactions with medical cannabis	11
Pharmacokinetics and safety of erenumab in pediatric patients with migraine: A phase I, randomized, open‐label, multiple‐dose study	11
Ascites affects the benefit of carvedilol on patients with liver cirrhosis and esophageal and gastric varices	11
Macrophage migration inhibitory factor predicts an unfavorable outcome after transarterial chemoembolization for hepatic malignancies	11
Updated DPYDHapB3 haplotype structure and implications for pharmacogenomic testing	11
	11
Issue Information	11
Immune‐viral dynamics modeling for SARS‐CoV‐2 drug development	11
Allelic variation in HLA‐DRB1 is associated with development of antidrug antibodies in cancer patients treated with atezolizumab that are neutralizing in vitro	10
Postmarket safety communications on drugs approved in Japan: A 25‐year analysis	10
Generic substitution of amlodipine is not associated with increased risk of mortality or adverse cardiovascular events: An observational cohort study	10
Pharmacokinetically guided dosing of oral sorafenib in pediatric hepatocellular carcinoma: A simulation study	10
Considerations for addressing anti‐vaccination campaigns: How did we get here and what can we do about it?	10
Pharmacogenomic‐based personalized medicine: Multistakeholder perspectives on implementational drivers and barriers in the Canadian healthcare system	10
Estimation of brain receptor occupancy for trazodone immediate release and once a day formulations	10

Pharmacokinetics, pharmacodynamics, and safety of frunexian in healthy Chinese volunteer adults: A randomized dose‐escalation phase I study	10
Population pharmacokinetic and exposure‐response analyses from ALTA‐1L: Model‐based analyses supporting the brigatinib dose in ALK‐positive NSCLC	10
Atogepant: Mechanism of action, clinical and translational science	10
Non‐synonymous alterations in AKR7A3 and ABCA6 correlate with bleeding in aged patients treated with rivaroxaban	10
Association between serum albumin to serum creatinine ratio and mortality risk in patients with heart failure	10
Potential biomarkers for fatal outcome prognosis in a cohort of hospitalized COVID‐19 patients with pre‐existing comorbidities	10
Subtyping treatment response of tirofiban in acute ischemic stroke based on neuroimaging features	10
Association of Vancomycin Plus Piperacillin‐Tazobactam With Acute Kidney Injury: Differentiating Pseudo‐Injury From True Nephrotoxicity	10
An exploratory machine learning approach to identify placebo responders in pharmacological binge eating disorder trials	10
Novel Bruton’s Tyrosine Kinase inhibitor remibrutinib: Drug‐drug interaction potential as a victim of CYP3A4 inhibitors based on clinical data and PBPK modeling	10
A randomized, controlled trial of prulifloxacin as conversion therapy after intravenous carbapenem in the treatment of acute pyelonephritis caused by third generation cephalosporin resistant pathogens	10
No drug–drug interactions between selective prolyl‐tRNA synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants	10
Evolution of preclinical characterization and insights into clinical pharmacology of checkpoint inhibitors approved for cancer immunotherapy	10
Informing Implementation Strategies for Pharmacogenomics in Cancer: Development of Survey Tools for Healthcare Professionals and Consumers	10
Remimazolam versus propofol in combination with esketamine for surgical abortion: A double‐blind randomized controlled trial	10
Cardiac sodium channel inhibition by lamotrigine: In vitro characterization and clinical implications	10
Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168)	10
Inflammation altered correlation between CYP2C19 genotype and CYP2C19 activity in patients receiving voriconazole	9
Surfing the T Wave: A Primer on ECG T Wave Morphologies Encountered in Clinical Trials and Impact on the QT Interval and Patient Safety	9
How can real‐world evidence aid decision making during the life cycle of nonprescription medicines?	9
Changing the drug development and therapeutic paradigm with biologic drug combinations and bispecifics: How to choose between these two approaches?	9
Expression of Concern: Liu, X., Zhong, L., Li, P., & Zhao, P. MicroRNA‐100 Enhances Autophagy and Suppresses Migration and Invasion of Renal Cell Carcinoma Cells via Disruption of NOX4‐Depe	9
Regulation of exosomes as biologic medicines: Regulatory challenges faced in exosome development and manufacturing processes	9
Population pharmacokinetics of iruplinalkib in healthy volunteers and patients with solid tumors	9
	9
Safety, Tolerability, and Pharmacokinetics of NIM‐1324 an Oral LANCL2 Agonist in a Randomized, Double‐Blind, Placebo‐Controlled Phase I Clinical Trial	9
First‐in‐human study of milvexian, an oral, direct, small molecule factor XIa inhibitor	9
Issue Information	9
Decentralized Clinical Trials in the Era of Real‐World Evidence: A Statistical Perspective	9
Corrigendum to: Integrating real‐world data and modeling to project changes in femoral neck bone mineral density and fracture risk in premenopausal women	9
	8
Effects of sevelamer carbonate versus calcium acetate on vascular calcification, inflammation, and endothelial dysfunction in chronic kidney disease	8
A longitudinal study of cytochrome P450 2D6 (CYP2D6) activity during adolescence	8
Age‐related off‐label drug prescribing in pediatric patients in South Korea and consistency of labeling compared to the United States, Europe, and Japan	8
Pharmacogenomic variation and sedation outcomes during early intensive care unit admission: A pragmatic study	8
Vericiguat in combination with isosorbide mononitrate in patients with chronic coronary syndromes: The randomized, phase Ib, VISOR study	8
BLOODPAC: Collaborating to chart a path towards blood‐based screening for early cancer detection	8
Developing a mechanistic translational PK/PD model for a trifunctional NK cell engager to predict the first‐in‐human dose for acute myeloid leukemia	8
Association of CYP2C19 genotypes with postoperative atrial fibrillation after coronary artery bypass surgery	8
Evaluation of Innate Immune System, Body Habitus, and Sex on the Pharmacokinetics and Pharmacodynamics of Anetumab Ravtansine in Patients With Cancer	8
Insights and lessons learned from a prospective clinical pharmacology study in allogeneic hematopoietic stem cell transplant during the COVID‐19 pandemic	8
Safety, Pharmacokinetics and Target Engagement of a Novel Brain Penetrant RIPK1 Inhibitor (SIR9900) in Healthy Adults and Elderly Participants	8
Controlled oxygenated rewarming as novel end‐ischemic therapy for cold stored liver grafts. A randomized controlled trial	8
Re‐discover the value of protein binding assessments in hepatic and renal impairment studies and its contributions in drug labels and dose decisions	8
Differential effects of metformin‐mediated BSEP repression on pravastatin and bile acid pharmacokinetics in humans: A randomized controlled trial	8
Evaluation of population‐level pharmacogenetic actionability in Alabama	8
Evaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole	8
Muscle velocity recovery cycles as pharmacodynamic biomarker: Effects of mexiletine in a randomized double‐blind placebo‐controlled cross‐over study	8
Association between psychomotor function and ALDH2 genotype after consuming barley shochu: A randomized crossover trial	8
Comparative effectiveness and safety of extended anticoagulant therapy among Medicare beneficiaries with venous thromboembolism	8
Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data	8
Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: A systematic review	8
Issue Information	8
Translational findings support regimen selection for first‐in‐human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer	8
What men want: Results from a national survey on decision making for prostate cancer treatment and research participation	8
Opportunities and challenges of 5G network technology toward precision medicine	8
A naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens	8
Global harmonization of immediate‐release solid oral drug product bioequivalence recommendations and the impact on generic drug development	8
Tutorial: Microbiome studies in drug metabolism	8
Optimizing a therapy for opiate use disorders: Characterizing ondansetron pharmacokinetics in blood and brain	8
Translational researchers’ training and development needs, preferences, and barriers: A survey in a National Institute for Health Research Biomedical Research Centre in the United Kingdom	8
Umbilical cord blood–derived exosomes from healthy term pregnancies protect against hyperoxia‐induced lung injury in mice	8
Pharmacokinetics, pharmacodynamics, and safety of fesomersen, a novel antisense inhibitor of factor XI, in healthy Chinese, Japanese, and Caucasian volunteers	8
Large‐Scale Analysis of Age and Sex Effects on Corrected QT and JT Intervals: Insights From Hospital‐Based Controls and Moxifloxacin‐Treated Cases	8
A linked physiologically based pharmacokinetic model for hydroxychloroquine and metabolite desethylhydroxychloroquine in SARS‐CoV‐2(−)/(+) populations	8
The expanding universe of NUTM1 fusions in pediatric cancer	7
Leveraging large observational studies to discover genetic determinants of drug concentrations: A proof‐of‐concept study	7
Pharmacokinetics of apixaban and tacrolimus or cyclosporine in kidney and lung transplant recipients	7
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral allosteric TYK2 inhibitor ESK‐001 using a randomized, double‐blind, placebo‐controlled study design	7
Clinical Outcomes and Safety Profiles of Generic Versus Brand‐Name Clopidogrel in Patients Following Coronary Artery Stent Placement	7
A call for reporting of tumor‐specific outcomes in studies of DPYD genotyping	7
Savor the flavor: A randomized double‐blind study assessing taste‐enhanced placebo analgesia in healthy volunteers	7
Strategic, feasibility, economic, and cultural aspects of phase 0 approaches	7
Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS‐CoV‐2	7
Biolink Model: A universal schema for knowledge graphs in clinical, biomedical, and translational science	7
Pharmacokinetic comparison of subcutaneously administered CT‐P13 (biosimilar of infliximab) via autoinjector and pre‐filled syringe in healthy participants	7
Thai pharmacogenomics database −2 (TPGxD‐2) sequel to TPGxD‐1, analyzing genetic variants in 26 non‐VIPGx genes within the Thai population	7
Lipid droplet screen in human hepatocytes identifies TRRAP as a regulator of cellular triglyceride metabolism	7
Facilitators and barriers to pediatric clinical trial recruitment and retention in rural and community settings: A scoping review of the literature	7
Factors explaining individual differences in the oral perception of capsaicin, l‐menthol, and aluminum ammonium sulfate	7
First‐in‐human study of deucravacitinib: A selective, potent, allosteric small‐molecule inhibitor of tyrosine kinase 2	7
PedCRIN tool for the biosamples management in pediatric clinical trials	7
Examining the effects of the HIV‐1 protein Tat and morphine on antiretroviral accumulation and distribution within the brain	7
	7
Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo‐controlled,	7
Rapid identification and phenotyping of nonalcoholic fatty liver disease patients using a machine‐based approach in diverse healthcare systems	7
Using exploratory pharmacokinetic and pharmacodynamic analyses to predict the probability of flu‐like symptoms in healthy volunteers and patients with chronic hepatitis B treated with the toll‐like re	7
Effect of enzalutamide on PK of P‐gp and BCRP substrates in cancer patients: CYP450 induction may not always predict overall effect on transporters	7
Pharmacokinetics, pharmacodynamics, and safety of asundexian in healthy Chinese and Japanese volunteers, and comparison with Caucasian data	7
Randomized evaluation of the loss‐of‐function carboxylesterase 1 (CES1) G143E variant on clopidogrel and ticagrelor pharmacodynamics	7
Continuous versus intermittent infusion of human antithrombin III concentrate in the immediate postoperative period after liver transplantation	7
Screening and characterization of myositis‐related autoantibodies in COVID‐19 patients	7
QPGx‐CARES: Qatar pharmacogenetics clinical applications and research enhancement strategies	7
Safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics of vutiglabridin: A first‐in‐class, first‐in‐human study	7
Issue Information	7